TuHURA Biosciences (NASDAQ:HURA) Raised to “Hold” at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Maxim Group cut their price objective on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Trading Down 3.1%

Shares of NASDAQ HURA opened at $1.90 on Friday. The firm has a fifty day simple moving average of $1.06 and a two-hundred day simple moving average of $1.70. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.44. The firm has a market capitalization of $115.37 million, a PE ratio of -3.80 and a beta of -0.33.

Hedge Funds Weigh In On TuHURA Biosciences

Several large investors have recently modified their holdings of HURA. Bank of America Corp DE purchased a new stake in TuHURA Biosciences during the 4th quarter valued at about $59,000. Jane Street Group LLC bought a new stake in shares of TuHURA Biosciences during the first quarter valued at approximately $69,000. Geode Capital Management LLC raised its holdings in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after acquiring an additional 307,260 shares during the last quarter. Intech Investment Management LLC bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $29,000. Finally, JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences during the 2nd quarter valued at $27,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.